Longeveron reports Q3 2026 results after ELPIS II trial and launches strategic review
FROM THE WIRE · GLOBENEWSWIRE.COM
Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps for the HLHS development program The Company has initiated a process to review all strategic options…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishClinical trial results and a strategic review weigh on the outlook of this small biotech.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The company requested a meeting with the FDA on ELPIS II results.
- 02It has initiated a review of all strategic options.
- 03Lucid Capital Markets was retained to explore opportunities, including a potential business combination.
- 04Cash conservation measures have been implemented.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets